June 6, 2019 / 5:21 AM / 3 months ago

BRIEF-Novartis Says Histology Data With Iscalimab Suggests Possible Extended Survival Of Transplanted Organs

June 6 (Reuters) - Novartis AG:

* NOVARTIS PRESENTS FIRST-OF-ITS-KIND HISTOLOGY DATA WITH ISCALIMAB (CFZ533) SUGGESTING EXTENDED SURVIVAL OF TRANSPLANTED ORGANS MAY BE POSSIBLE

* DATA SHOW 60% OF ISCALIMAB-TREATED TRANSPLANT PATIENTS HAVE NORMAL KIDNEY HISTOLOGY AT LEAST 1 YEAR AFTER TRANSPLANT VERSUS 0% WITH TACROLIMUS (CURRENT STANDARD OF CARE)

* FINDINGS, ALTHOUGH IN A LIMITED NUMBER OF PATIENTS, ARE TO BE CONFIRMED IN AN ONGOING PHASE IIB TRIAL Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below